Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1842-1847

  Seki, Ritsuko ^a,b   Ohshima, Koichi ^a,b   Fujisaki, Tomoaki ^c   Uike, Naokuni ^d   Kawano, Fumio ^e   Gondo, Hisashi ^f   Makino, Shigeyoshi ^g   Eto, Tetsuya ^h   Moriuchi, Yukiyoshi ⁱ   Taguchi, Fumihiro ^j   Kamimura, Tomohiko ^k   Tsuda, Hiroyuki ^l   Ogawa, Ryosuke ^m   Shimoda, Kazuya ⁿ   Yamashita, Kiyoshi ⁿ   Suzuki, Keiko ^o   Suzushima, Hitoshi ^p   Tsukazaki, Kunihiro ^q   Higuchi, Masakazu ^r   Utsunomiya, Atae ^s   Iwahashi, Masahiro ^t   Imamura, Yutaka ^u   Tamura, Kazuo ^v   Suzumiya, Junji ^w   Yoshida, Minoru ^x   Abe, Yasunobu ^y   Matsumoto, Tadashi ^z   Okamura, Takashi ^a,b   more..

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^f Saga Prefectural Hospital   (Japan)

^g MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^h HAMANOMACHI HOSPITAL   (Japan)

ⁱ Sasebo Shiritsu Sogo Hospital   (Japan)

^j ASO IIZUKA HOSPITAL   (Japan)

^k HARASANSHIN HOSPITAL   (Japan)

^l KUMAMOTO CITY HOSPITAL   (Japan)

^m Shimonoseki City Hospital   (Japan)

ⁿ UNIVERSITY OF MIYAZAKI   (Japan)

^o Koga General Hospital   (Japan)

^p NTT Kyushu General Hospital   (Japan)

^q NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^r KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^s IMAMURA BUN IN HOSPITAL   (Japan)

^t Saiseikai Hita Hospital   (Japan)

^u ST MARY S HOSPITAL   (Japan)

^v FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^w Fukuoka University Chikushi Hospital   (Japan)

^x JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^y KYUSHU UNIVERSITY   (Japan)

^z Imamura Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERFERON REGULATORY FACTOR 4; METHOTREXATE; PREDNISOLONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 70349603639     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01268.x     Document Type: Article

References (34)

1. Okamura T. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-94.
2. Kramer MH, Hermans J, Wijburg E. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92:3152-62.
3. Fisher RI, Gaynor ER, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-6.
4. Coiffier B, Lepage E, Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-42.
5. Habermann TM, Weller EA, Morrison VA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-7.
6. Pfreundschuh M, Trumper L, Osterborg A. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-91.
7. Sehn LH, Donaldson J, Chhanabhai M. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-33.
8. Iqbal J, Neppalli VT, Wright G. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:961-8.
9. Lossos IS, Jones CD, Warnke R. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001, 98:945-51.
10. Mounier N, Briere J, Gisselbrecht C. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003, 101:4279-84.
11. Winter JN, Weller EA, Horning SJ. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006, 107:4207-13.
12. Gascoyne RD, Adomat SA, Krajewski S. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-51.
13. Hermine O, Haioun C, Lepage E. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996, 87:265-72.
14. Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-11.
15. Shipp MA, Ross KN, Tamayo P. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
16. Rosenwald A, Wright G, Chan WC. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-47.
17. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:995-1007.
18. Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-82.
19. Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
20. Jaffe ES, Harris NL, Stein H. Pathology and Genetics of Tumors of the Hematopoietic and Lymphoid Tissues 2001, Lyon, France, International Agency for Research on Cancer Press
21. Guo Y, Karube K, Kawano R. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia 2005, 19:1058-63.
22. Cox DR. Regression models and life tables. J R Stat Soc B 1972, 74:187-220.
23. Nyman H, Adde M, Karjalainen-Lindsberg ML. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007, 109:4930-5.
24. Haarer CF, Roberts RA, Frutiger YM. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006, 130:1819-24.
25. Sehn LH, Berry B, Chhanabhai M. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-61.
26. Feugier P, Van Hoof A, Sebban C. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-26.
27. Lossos IS, Czerwinski DK, Alizadeh AA. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350:1828-37.
28. Wilson WH, Dunleavy K, Pittaluga S. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008, 26:2717-24.
29. de Jong D, Rosenwald A, Chhanabhai M. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007, 25:805-12.
30. de Jong D, Xie W, Rosenwald A. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009, 62:128-38.
31. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-γB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264-76.
32. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005, 24:2121-43.
33. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005, 175:2174-83.
34. Fu K, Weisenburger DD, Choi WW. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008, 26:4587-94.